Gore makes tracks with next-gen tech for hole-in-heart defects
This article was originally published in Clinica
Executive Summary
WL Gore & Associates has kicked off clinical trials of its next-generation Gore septal occluder (GSO), which could support US FDA approval of the product for the treatment of atrial septal defects (ASDs) and patent foramen ovale (PFO), two forms of congenital heart defects.